The Research Pharmacy Core has a well-developed system for the monitoring, coordination, and support of research pharmacy activities at DF/HCC member institutions. This facility has been approved and funded by the CCSG since 2004, when it received excellent merit. The Core assures consistency in policies across the sites (including policies relating to the receipt, storage, formulation, and dispensation of investigational agents), facilitates best practices, and monitors perfonnance through a quality assurance program coordinated through the inter-institutional Research Pharmacy Core Committee. The Research Pharmacy participates in the DF/HCC Scientific Review and Monitoring Committees (PRMS) and Data and Safety Monitoring (DSM) program, as well as other relevant Cancer Center clinical trials oversight, monitoring, and policy initiatives.

Public Health Relevance

The Research Pharmacy enables DF/HCC clinical investigators to conduct cancer-relevant research with a minimum of organizational encumbrances and differences in practice. The Research Pharmacy serves as a central point for the unification and integration of research-related pharmacy activities, fostering a coordinated clinical trials program within a multi-institution Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
4P30CA006516-51
Application #
8975654
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
2017-11-30
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
51
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121
Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538
Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609

Showing the most recent 10 out of 411 publications